Cargando…
First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone
Synthetic cannabinoids- (SCs-) induced psychosis is a growing public health concern. It leads to significant impairment, including emotional distress, difficulty communicating, and other debilitating symptoms. In this case report, we discuss a patient with no previous history of psychotic symptoms,...
Autores principales: | Roberto, Aaron J., Lorenzo, Aileen, Li, Kevin J., Young, Jonathan, Mohan, Abhishek, Pinnaka, Subhash, Lapidus, Kyle A. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939204/ https://www.ncbi.nlm.nih.gov/pubmed/27429822 http://dx.doi.org/10.1155/2016/7257489 |
Ejemplares similares
-
Adolescent Catatonia Successfully Treated with Lorazepam and Aripiprazole
por: Roberto, Aaron J., et al.
Publicado: (2014) -
Effects of Risperidone on Cytokine Profile in Drug-Naïve First-Episode Psychosis
por: Noto, Cristiano, et al.
Publicado: (2015) -
Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naive first-episode psychosis patients
por: Birur, Badari, et al.
Publicado: (2020) -
Very Low-Dose Risperidone in First-Episode Psychosis: A Safe and Effective Way to Initiate Treatment
por: McGorry, Patrick D., et al.
Publicado: (2011) -
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
por: Borgan, Faith, et al.
Publicado: (2019)